PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.72%
EBIT growth 50-75% of AXSM's 12.01%. Martin Whitman would suspect suboptimal resource allocation.
7.72%
Operating income growth at 50-75% of AXSM's 12.01%. Martin Whitman would doubt the firm’s ability to compete efficiently.
12.50%
Net income growth comparable to AXSM's 11.39%. Walter Schloss might see both following similar market or cost trajectories.
15.94%
EPS growth at 50-75% of AXSM's 26.83%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
15.94%
Diluted EPS growth at 50-75% of AXSM's 26.83%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
4.10%
Share reduction more than 1.5x AXSM's 20.77%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
4.10%
Diluted share reduction more than 1.5x AXSM's 20.77%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-32.84%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-32.79%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-48098.63%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-29341.33%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-23.11%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-39968.68%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-32.05%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-188.96%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
7755.72%
Equity/share CAGR of 7755.72% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2687.68%
Equity/share CAGR of 2687.68% while AXSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-9.18%
Negative 3Y equity/share growth while AXSM is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-33.82%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-14.34%
We cut SG&A while AXSM invests at 3.35%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.